- Antihistamines
- Corticosteroids
- Decongestants
- Combination Drugs
- Antibiotics
- Acid Blockers
- Others
Chronic Cough Market size was valued at USD 7845 million in 2023 and is poised to grow at a CAGR of 8% over 2024-2030. A chronic cough is a cough that lasts eight weeks or longer, and the most common causes include tobacco use, postnasal drip, asthma, and acid reflux. Based on the drug class, the combination drugs segment is anticipated to dominate the market share over the forecast period.
`According to the report from several studies, the worldwide prevalence of chronic cough was estimated as 9.6%, whereas the incidence rate ranged from 1.16 to 5.70 per 100 person-years. The rising prevalence of chronic cough and increased global healthcare expenditure will act as the chronic cough market growth drivers. However, the high cost of treatment would be the lagging factor for the market. The development of novel technologies for diagnosis and novel drug development to treat chronic cough are opportunities for pharmaceutical companies for market expansion.
Chronic Cough Market Key Developments:
- In Oct 2019, Aurobindo Pharma received final approval from the US FDA to manufacture generic Guaifenesin extended-release tablets, for chronic cough.
- In Jan 2022, the US FDA approved Merck’s Gefapixant, a non-narcotic, oral selective P2X3 receptor antagonist for the treatment of patients with unexplained chronic cough.
Chronic Cough Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
8%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Chronic Cough Market Dynamics
The various initiatives from pharmaceutical companies and governments towards launching more drugs for chronic cough will be major factors for the chronic cough market expansion. For example, Nocion Therapeutics conducted a phase-I trial for cough in the USA for NOC 100. Whereas lack of training for healthcare professionals and product recalls could be the restraining factor for the market. For instance, in June 2020, GSK had to recall “Children’s Robitussin Honey Cough and Chest Congestion DM” and “Children’s Dimetapp Cold and Cough” due to “incorrect dosage cups”. Thus, the increased awareness, research, and development for chronic respiratory disorders will lead to the growth of the market within the forecast period.
Key Features of the Reports
- The chronic cough market report provides granular level information about the market size, regional market share, historic market (2019-2023) and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Chronic Cough Market Segmentation
By Drug Class
By Route of Administration
- Oral
- Injections
- Inhalations
- Others
By End User
- Hospitals
- Clinics
- Homecare
- Others
Frequently Asked Questions
The Chronic Cough market was valued at USD 7845 million in 2023 and is expected to grow at a 8% CAGR over the forecast period 2024 – 2030.
The development of novel technologies for diagnosis and novel drug development to treat chronic cough are the key opportunities for the Chronic Cough market.
The rising prevalence of chronic cough and increased global healthcare expenditure are the growth drivers in the Chronic Cough market.
Merck KGaA, Novartis AG, Johnson & Johnson Private Limited, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Biocon, Bristol-Myers Squibb Company, and GSK plc. are a few companies operating in the Chronic Cough market.
| 1.Executive Summary |
| 2.Global Chronic Cough Market Introduction |
| 2.1.Global Chronic Cough Market - Taxonomy |
| 2.2.Global Chronic Cough Market - Definitions |
| 2.2.1.Drug Class |
| 2.2.2.Route of Administration |
| 2.2.3.End User |
| 2.2.4.Region |
| 3.Global Chronic Cough Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Chronic Cough Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Chronic Cough Market By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Antihistamines |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Corticosteroids |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Decongestants |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Combination Drugs |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Antibiotics |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Acid Blockers |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Others |
| 5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 6.Global Chronic Cough Market By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Oral |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Injections |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Inhalations |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Others |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7.Global Chronic Cough Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospitals |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Clinics |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Homecare |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Others |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8.Global Chronic Cough Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Chronic Cough Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Antihistamines |
| 9.1.2.Corticosteroids |
| 9.1.3.Decongestants |
| 9.1.4.Combination Drugs |
| 9.1.5.Antibiotics |
| 9.1.6.Acid Blockers |
| 9.1.7.Others |
| 9.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Oral |
| 9.2.2.Injections |
| 9.2.3.Inhalations |
| 9.2.4.Others |
| 9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospitals |
| 9.3.2.Clinics |
| 9.3.3.Homecare |
| 9.3.4.Others |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Chronic Cough Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Antihistamines |
| 10.1.2.Corticosteroids |
| 10.1.3.Decongestants |
| 10.1.4.Combination Drugs |
| 10.1.5.Antibiotics |
| 10.1.6.Acid Blockers |
| 10.1.7.Others |
| 10.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Oral |
| 10.2.2.Injections |
| 10.2.3.Inhalations |
| 10.2.4.Others |
| 10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospitals |
| 10.3.2.Clinics |
| 10.3.3.Homecare |
| 10.3.4.Others |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Chronic Cough Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Antihistamines |
| 11.1.2.Corticosteroids |
| 11.1.3.Decongestants |
| 11.1.4.Combination Drugs |
| 11.1.5.Antibiotics |
| 11.1.6.Acid Blockers |
| 11.1.7.Others |
| 11.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Oral |
| 11.2.2.Injections |
| 11.2.3.Inhalations |
| 11.2.4.Others |
| 11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospitals |
| 11.3.2.Clinics |
| 11.3.3.Homecare |
| 11.3.4.Others |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Chronic Cough Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Antihistamines |
| 12.1.2.Corticosteroids |
| 12.1.3.Decongestants |
| 12.1.4.Combination Drugs |
| 12.1.5.Antibiotics |
| 12.1.6.Acid Blockers |
| 12.1.7.Others |
| 12.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Oral |
| 12.2.2.Injections |
| 12.2.3.Inhalations |
| 12.2.4.Others |
| 12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospitals |
| 12.3.2.Clinics |
| 12.3.3.Homecare |
| 12.3.4.Others |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Chronic Cough Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Antihistamines |
| 13.1.2.Corticosteroids |
| 13.1.3.Decongestants |
| 13.1.4.Combination Drugs |
| 13.1.5.Antibiotics |
| 13.1.6.Acid Blockers |
| 13.1.7.Others |
| 13.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Oral |
| 13.2.2.Injections |
| 13.2.3.Inhalations |
| 13.2.4.Others |
| 13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospitals |
| 13.3.2.Clinics |
| 13.3.3.Homecare |
| 13.3.4.Others |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Merck KGaA |
| 14.2.2.Novartis AG |
| 14.2.3.Johnson & Johnson Private Limited |
| 14.2.4.Mylan N.V. |
| 14.2.5.Teva Pharmaceutical Industries Ltd. |
| 14.2.6.Sanofi |
| 14.2.7.Sun Pharmaceutical Industries Ltd. |
| 14.2.8.Aurobindo Pharma |
| 14.2.9.Biocon |
| 14.2.10.Bristol-Myers Squibb Company |
| 14.2.11.GSK plc. |
| 14.2.12.NeRRe Therapeutics |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Merck KGaA
- Novartis AG
- Johnson & Johnson Private Limited
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Biocon
- Bristol-Myers Squibb Company
- GSK plc.
- NeRRe Therapeutics